ArticleThe Prostate2014

Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells.

Chengfei Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.